Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Washington University School of Medicine

Sites in St. Louis, MO

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1752
Shown on this page
12
Current sort
Recently updated
Campus scope
Washington University School of Medicine, St. Louis, MO
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Washington University School of Medicine, St. Louis, MO. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 349–360 of 1,752 matching trials with a site at Washington University School of Medicine, St. Louis, MO.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional

PREEMIE: Study for Treatment of PDA in Premature Infants

NCT06587282
Site status not listed — check the official record
View directory record Official record
Conditions
Patent Ductus Arteriosus (PDA)
Interventions
Bloom Micro Occluder System
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
5 Days and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Sacramento, California • San Diego, California • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 2 Interventional

CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma

NCT07659678
Status at this site: Recruiting
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Head and Neck Squamous Cell Carcinoma HNSCC
Interventions
64Cu-DOTA-ECL1i
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

BoxX-NoAF Clinical Trial

NCT06989775
Status at this site: Recruiting
View directory record Official record
Conditions
Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
Interventions
Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
65 Years and older
Enrollment
960 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
33
States / cities
Scottsdale, Arizona • Jonesboro, Arkansas • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Hurria Older PatiEnts (HOPE) With Breast Cancer Study

NCT01472094
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 1 Interventional

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Esophageal Neoplasms
Interventions
LY4257496, Standard of Care Anticancer Therapies, LY4257529
Drug · Diagnostic Test
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
16
States / cities
Duarte, California • Santa Monica, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

NCT06338995
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
LY3650150, Placebo, Standard therapy for INCS
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677
Status at this site: Recruiting
View directory record Official record
Conditions
Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
Interventions
Surgery, Preoperative chemotherapy
Procedure · Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
116
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 92 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting No phase listed Observational

Health Outcomes of Parents With Cystic Fibrosis-Aim 2

NCT06296394
Status at this site: Recruiting
View directory record Official record
Conditions
Cystic Fibrosis, Parenthood Status
Interventions
Parenthood
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Denver, Colorado • Evanston, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 4 Interventional

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

NCT07569926
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Prostate Cancer
Interventions
fluciclovine (18F)
Drug
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

NCT04844606
Status at this site: Recruiting
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 19 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT04071236
Site status not listed — check the official record
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT
Recruiting Phase 3 Interventional

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099
Status at this site: Recruiting
View directory record Official record
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:44 PM EDT

About this Washington University School of Medicine institution page

What this page lists
ClinicalTrials.gov records that list Washington University School of Medicine in St. Louis, MO as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Washington University School of Medicine at any site, browse by condition, or browse by U.S. city.